Can Insilico Medicine’s rentosertib slow FVC decline in Phase 3 IPF study?
Insilico Medicine starts Phase 3 testing of rentosertib in IPF, putting its AI-discovered TNIK inhibitor through a decisive 52-week trial.
Pharma & Biotech
Pharma & Biotech
Can an inhaled peptide do more than slow lung fibrosis? Rein Therapeutics moves LTI-03 deeper into Phase 2
FDA Fast Track gives Rein Therapeutics closer regulatory access as its 120-patient RENEW trial tests whether inhaled LTI-03 can translate promising biomarker effects into measurable preservation of lung function.
Pharma & Biotech
Could deupirfenidone beat an approved IPF drug? Celea starts the Phase 3 test that will decide
Celea Therapeutics has begun an unusually ambitious Phase 3 program designed to prove that deupirfenidone is superior, rather than merely comparable, to the established antifibrotic pirfenidone. The approximately 1,100-patient trial could support a United States registration application if successful, but its 2029 readout leaves the company facing a long development period and an increasingly competitive
Pharma & Biotech
Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Contineum Therapeutics paper sharpens PIPE-791 case, but Phase 2 IPF data remain decisive
Discover why Contineum Therapeutics’ PIPE-791 paper strengthens the LPAR1 case while Phase 2 IPF data remain the decisive clinical test.
Pharma & Biotech
Could Simcere’s Stanford Medicine IPF deal expose the next big gap in fibrosis treatment?
Find out how Simcere and Stanford Medicine’s IPF collaboration could reshape early-stage antifibrotic drug discovery.
Pharma & Biotech
Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.
Pharma & Biotech
Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF
Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.
Pharma & Biotech
Why the market will watch Calluna Pharma’s CAL101 more closely after AURORA enrollment ends ahead of plan
Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.
Pharma & Biotech
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.